JEEP — orange-cap Tirzepatide T30, January 2026 batch
This is one entry from the TitrateLab Vendor Graveyard, a dated archive of peptide-market shutdowns, buyer-loss reports and enforcement actions. Documented as April 2026. Evidence tier: Documented record. Sources for this entry are linked inline below and annotated in the full Vendor Graveyard entry.
A Janoshik certificate reports 2,306 EU of endotoxin per vial on JEEP’s January 2026 orange-cap tirzepatide 30 mg batch. At a 15 mg dose that is about 3.3 times the per-dose ceiling derived from USP <85> for a 70 kg adult; at the 2.5 mg starting dose it is under the ceiling.
On who ran the test. The assays were run by Janoshik. “LS Group Testing” is the community group-buy cohort that organised, funded and submitted the samples, not a laboratory; the submission is logged at Janoshik under the client name “EPU x LS Group Testing GB x juGGakNot Empire”. An earlier version of this entry named LS as the testing lab in one place and LiquiLabs in another. Both were wrong, and we have corrected them.
JEEP (also written “JEEPJEEP”) is a China-based research-peptide vendor with an active vendor account in the GLP-1 Forum marketplace.
Timeline:
- January 2026. JEEP ships orange-cap tirzepatide 30 mg (“T30”) from the batch later tested. The source thread says this batch kept the batch number printed on earlier stock and differed only by a slightly lighter cap.
- March 13, 2026. Janoshik’s first endotoxin result on the batch (#113887) estimates 1,350 EU per vial. The report states that values above 100 EU/vial are outside the assay’s validated range at that dilution.
- April 8, 2026. Two more vials from the same batch, donated by buyers in different countries, return 1,360 EU per vial (#136051, again an estimate above the validated range) and 2,306 EU per vial (#136052, reported as a value with no range note). The cohort posts a safety warning on GLP-1 Forum the same day. EU means endotoxin units. USP <85> does not require an undetectable result; for parenteral drugs other than intrathecal it uses a threshold of 5 EU per kg, which for a 70 kg adult is 350 EU per dose. The relevant question is what a single injection delivers, not what a vial contains.
| Vial | Certificate | Dilution range | Endotoxin | Per 15 mg dose | vs. 350 EU ceiling |
|---|---|---|---|---|---|
| #1 | #113887, Mar 13 | 10–100 | 1,350 EU/vial (estimate) | 675 EU | 1.9× |
| #2 | #136051, Apr 8 | 100–1000 | 1,360 EU/vial (estimate) | 680 EU | 1.9× |
| #3 | #136052, Apr 8 | 1000+ | 2,306 EU/vial | 1,153 EU | 3.3× |
What the numbers do and do not say. Endotoxin per vial is fixed; endotoxin per injection scales with how much of the vial is drawn. On these three vials a 2.5 mg dose delivers 113 to 192 EU, under the 350 EU ceiling. The 1,350 and 1,360 EU vials reach the ceiling at about 7.8 mg per dose, and the 2,306 EU vial at about 4.6 mg. These are per-dose comparisons against a 70 kg reference weight; they do not describe any individual’s response.
Our corpus holds all three Janoshik certificates. Only the 2,306 EU/vial result is reported as a value; the 1,350 and 1,360 EU/vial readings are estimates above the assay’s validated range, so they show the vials were high without fixing the exact load. A separate Janoshik assay of the same batch (#124223, analysed March 24, 2026) measured 32.72 to 35.10 mg of tirzepatide at 99.89% average purity: the cohort’s finding concerns endotoxin, not content or purity.
Later results. As of October 1, 2026 our corpus holds seven JEEP tirzepatide results with an endotoxin reading dated after April 8: April 22 to September 19, 2026, from Finnrick public submissions and Freedom Diagnostics. Three read low, one below the limit of quantitation, one negative and two pass. None failed. Two describe orange-cap vials with printed batch codes JP20250616 and JP20250617. Because the source thread says the January batch kept the batch number printed on earlier stock, a printed code cannot place a vial inside or outside that batch, and we cannot treat either result as a retest of it. The thread said the cohort’s vials were being retested, including the first kit at LiquiLabs; we have found no published result of those retests.
Why endotoxin is tested. Endotoxins are lipopolysaccharides from the outer membrane of Gram-negative bacteria. Above threshold doses, injected endotoxin can cause fever and inflammatory reactions, which is why USP <85> sets a per-dose limit for injectable products.
Why this points at the batch, and what cuts against it. The source thread reports that the vials came from different buyers’ separate purchases of the same January batch. If so, a result that recurs across three of them points at the production lot rather than at one buyer’s handling. The same thread reports that one cohort member’s sample, sent to a different laboratory (Trustpointe), returned 110 EU. The post gives no unit basis and says the cohort was checking whether the figure was an estimate outside the assay’s range; we hold no certificate for it.
The January 2026 orange-cap T30 batch carries a certificate-backed endotoxin result above the per-dose ceiling at doses of about 4.6 mg and higher. We have no evidence that other JEEP batches share it: the seven later tirzepatide endotoxin results in our corpus did not fail. We continue to ingest JEEP-tagged third-party tests.
Evidence tier: Documented record.
Sources: Janoshik certificates #113887, #136051 and #136052, and assay #124223; GLP-1 Forum safety-warning thread, April 8, 2026; USP <85>; TitrateLab COA corpus, checked October 1, 2026.
Related TitrateLab research: Endotoxins in 2026: What Grey-Market Peptide Reports Show places this batch’s Janoshik report 136052 (2,306 EU/vial) in the wider grey-market endotoxin record.